» Articles » PMID: 33790023

Transcriptional Networks in At-risk Individuals Identify Signatures of Type 1 Diabetes Progression

Abstract

Type 1 diabetes (T1D) is a disease of insulin deficiency that results from autoimmune destruction of pancreatic islet β cells. The exact cause of T1D remains unknown, although asymptomatic islet autoimmunity lasting from weeks to years before diagnosis raises the possibility of intervention before the onset of clinical disease. The number, type, and titer of islet autoantibodies are associated with long-term disease risk but do not cause disease, and robust early predictors of individual progression to T1D onset remain elusive. The Environmental Determinants of Diabetes in the Young (TEDDY) consortium is a prospective cohort study aiming to determine genetic and environmental interactions causing T1D. Here, we analyzed longitudinal blood transcriptomes of 2013 samples from 400 individuals in the TEDDY study before both T1D and islet autoimmunity. We identified and interpreted age-associated gene expression changes in healthy infancy and age-independent changes tracking with progression to both T1D and islet autoimmunity, beginning before other evidence of islet autoimmunity was present. We combined multivariate longitudinal data in a Bayesian joint model to predict individual risk of T1D onset and validated the association of a natural killer cell signature with progression and the model's predictive performance on an additional 356 samples from 56 individuals in the independent Type 1 Diabetes Prediction and Prevention study. Together, our results indicate that T1D is characterized by early and longitudinal changes in gene expression, informing the immunopathology of disease progression and facilitating prediction of its course.

Citing Articles

Looking back at the TEDDY study: lessons and future directions.

Lernmark A, Agardh D, Akolkar B, Gesualdo P, Hagopian W, Haller M Nat Rev Endocrinol. 2024; 21(3):154-165.

PMID: 39496810 PMC: 11825287. DOI: 10.1038/s41574-024-01045-0.


Emerging Concepts and Success Stories in Type 1 Diabetes Research: A Road Map for a Bright Future.

Mallone R, Sims E, Achenbach P, Mathieu C, Pugliese A, Atkinson M Diabetes. 2024; 74(1):12-21.

PMID: 39446565 PMC: 11664023. DOI: 10.2337/db24-0439.


Immune perturbations in human pancreas lymphatic tissues prior to and after type 1 diabetes onset.

Golden G, Wu V, Hamilton J, Amses K, Shapiro M, Japp A bioRxiv. 2024; .

PMID: 39345402 PMC: 11429609. DOI: 10.1101/2024.04.23.590798.


Bayesian clustering with uncertain data.

Nicholls K, Kirk P, Wallace C PLoS Comput Biol. 2024; 20(9):e1012301.

PMID: 39226325 PMC: 11398681. DOI: 10.1371/journal.pcbi.1012301.


A Review of Stage 0 Biomarkers in Type 1 Diabetes: The Holy Grail of Early Detection and Prevention?.

Manescu M, Manescu I, Grama A J Pers Med. 2024; 14(8).

PMID: 39202069 PMC: 11355657. DOI: 10.3390/jpm14080878.


References
1.
Cabrera S, Chen Y, Hagopian W, Hessner M . Blood-based signatures in type 1 diabetes. Diabetologia. 2015; 59(3):414-25. PMC: 4744128. DOI: 10.1007/s00125-015-3843-x. View

2.
Nepom G, Ehlers M, Mandrup-Poulsen T . Anti-cytokine therapies in T1D: Concepts and strategies. Clin Immunol. 2013; 149(3):279-85. PMC: 3700624. DOI: 10.1016/j.clim.2013.02.003. View

3.
Aldridge S, Teichmann S . Single cell transcriptomics comes of age. Nat Commun. 2020; 11(1):4307. PMC: 7453005. DOI: 10.1038/s41467-020-18158-5. View

4.
Rodgers G, Austin C, Anderson J, Pawlyk A, Colvis C, Margolis R . Glimmers in illuminating the druggable genome. Nat Rev Drug Discov. 2018; 17(5):301-302. PMC: 6309548. DOI: 10.1038/nrd.2017.252. View

5.
Langfelder P, Horvath S . WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008; 9:559. PMC: 2631488. DOI: 10.1186/1471-2105-9-559. View